MHRAsafety guidance72% confidence
Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension
Source: MHRA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (cardiology) as Merck.
Regulatory Analysis
The product information has been updated for all domperidone products, to include a contraindication for patients with confirmed or suspected phaeochromocytoma (a rare tumour of the adrenal gland), due to the risk of episodes of severe hypertension.
Supporting Context
- Therapeutic area
- Pulmonary Arterial Hypertension · Targeted Therapy
- Sub-indication
- Hypertension
Related signal: Merck initiates long-term study on Sotatercept for Pulmonary Arterial Hypertension